Hyperfine, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 22, 2024. This is an annual filing, not a standalone fourth-quarter report, so the filing text does not provide clear Q4-only financial results.
Business context
Hyperfine develops and commercializes the Swoop portable, ultra-low-field brain MRI system, together with related service and support. The system is FDA-cleared for brain imaging in patients of all ages and has authorizations in several international markets. The company has focused resources on Swoop after suspending its Liminal brain-sensing program in 2022.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $11.0 million | $6.8 million |
| Gross profit | $4.8 million | $0.9 million |
| Gross margin | 43.1% | 13.3% |
| Operating expenses | $52.9 million | $74.8 million |
| Operating loss | $48.1 million | $73.9 million |
| Net loss | $44.2 million | $73.2 million |
| Net cash used in operations | $41.8 million | $72.3 million |
Revenue grew 61.9%; device revenue rose 66.7% and service revenue 45.8%. Management attributed growth to higher average selling prices, more units sold, and a larger installed base. Units sold increased 5.7% to 37. Non-U.S. revenue was $4.36 million, or about 40% of total revenue. Lower operating expenses and higher interest income contributed to the narrower net loss.
At year-end, cash and cash equivalents were $75.2 million, restricted cash was $0.6 million, total assets were $94.2 million, and total liabilities were $9.8 million. The balance sheet lists no interest-bearing debt. Management expects existing cash and anticipated product and service proceeds to fund planned operations for at least 12 months, while warning that this depends on its plans and revenue prospects. The company reported no income tax provision and a full valuation allowance against deferred tax assets.
Changes, outlook, risks, and unusual items
- The 2022 restructuring, completed in Q1 2023, reduced headcount by approximately 13%; cumulative restructuring charges were $1.016 million. The company continues to prioritize Swoop.
- Management plans continued product and AI/software development, U.S. commercialization, and selective international expansion. It gave no quantified revenue, earnings, or unit-sales guidance.
- A November 2023 shelf registration permits up to $150 million of securities and includes a $50 million at-the-market equity program. No ATM shares had been sold by year-end. The company disclosed that SEC “baby shelf” limits constrain primary offerings while public float remains below $75 million.
- Material risks include ongoing losses and cash burn; uncertain market adoption and reimbursement; reliance on Benchmark as sole finished-device manufacturer and on limited/single-source component suppliers, including a European magnet supplier; competition; regulatory, clinical, privacy and cybersecurity risks; and potential need for additional financing. Two customers represented at least 10% of revenue in 2023, and two customers each exceeded 10% of year-end receivables and unbilled receivables.
- The company reported no material legal proceedings and no material cybersecurity incidents in the prior two fiscal years. Management stated prior material weaknesses in internal control were remediated in 2023; management assessed controls as effective at year-end, but the external auditor was not engaged to opine on internal-control effectiveness.
Investor facts to verify
- Whether Swoop adoption, renewals, and average selling prices can sustain revenue growth and improve gross margins.
- Cash-burn trends, working-capital needs, and the expected timing and terms of any equity financing, including baby-shelf limitations and dilution.
- Supplier diversification progress and inventory quality; inventory increased to $6.6 million from $4.6 million.
- Clinical-study progress and evidence supporting planned stroke and Alzheimer’s applications, plus regulatory and reimbursement requirements.
- Customer concentration, the 40% international revenue share, and the implications of Jonathan Rothberg’s approximately 85% voting control through the dual-class structure.